Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Bitcoin’s Price Wavers After The Release of New Inflation Data
-
Baker Hughes Slips On Disappointing Q2 Results, Outlook
-
BTC Bull Run Incoming? Bitcoin Supply on Exchanges Hits Six-Year Low
-
Bloomberg Strategist: In Aftermath of FTX Collapse, Bitcoin Could Revisit $10K Support
-
Inflation Fears Keep World Markets Jittery